Insights

API (ASX:API) share price rockets 16% as Wesfarmers boosts offer

Wesfarmers has moved one step closer to adding another company to its retail portfolio.
The post API (ASX:API) share price rockets 16% as Wesfarmers boosts offer appeared first on The Motley Fool Australia. –

The Australian Pharmaceutical Industries Ltd (ASX: API) share price has had a jolt of enthusiasm on Thursday. This comes after the retail pharmacy company received a revised acquisition offer from Wesfarmers Ltd (ASX: WES).

All the excitement has propelled the API share price 16.5% higher to $1.48 at the time of writing.

Today’s offer follows previous attempts from the retail conglomerate to acquire API. However, these prior attempts have been futile, with API rejecting the unsatisfactory offers.

Let’s inspect the latest proposal more closely.

A sweetened API share price offer

It appears whatever API has got, Wesfarmers wants it badly. At least, badly enough to amp up its bid for the pharmaceutical retailer by 12.3% to $1.55 per share. After being rejected in July for its $1.38 proposal, Wesfarmers firmly has its sights set on doing a deal.

The revised offer for 100% of outstanding API shares comes to a total cash consideration of $764 million. This proposal also provides for the final fully franked dividend payment up to a maximum of 5 cents per share. However, any such cash component of dividends paid will come out of the total cash payment.

It appears the sweetened API share price offering has gained the blessings of the company’s largest shareholder, Washington H. Soul Pattinson and Co. Ltd (ASX: SOL). Recent data shows the investment conglomerate holds ownership of 18% of outstanding API shares.

Likewise, the board of Australian Pharmaceuticals intends to unanimously recommend the revised proposal. Which leaves the finalisation of acquisition down to due diligence and regulatory approvals.

What’s management’s thoughts?

Commenting on the revised bid, API CEO and managing director Richard Vincent said:

This revised offer better reflects the strength and potential of our stable of businesses that have been built by the efforts and passion of all of our people within API. Aligned with our vision of “enriching life”, we remain firmly focused on making a difference for all our customers and trading partners.

According to the release, Wesfarmers will have until 16 October to conduct its due diligence under the Process Deed.

Thanks to the surge in the API share price, the company now boasts a market capitalisation of $729 million.

The post API (ASX:API) share price rockets 16% as Wesfarmers boosts offer appeared first on The Motley Fool Australia.

Should you invest $1,000 in Australian Pharmaceutical Industries right now?

Before you consider Australian Pharmaceutical Industries, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Australian Pharmaceutical Industries wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Wesfarmers (ASX:WES) share price edges higher on sweetened API bid
ASX 200 (ASX:XJO) midday update: Telstra unveils T25 strategy, Wesfarmers’ API offer

The Wesfarmers (ASX:WES) share price is up 28% in 2021. Here’s why

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Wesfarmers Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!